Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Rallybio is a clinical-stage biotechnology company focused on developing therapies for severe and rare diseases. Its pipeline includes product candidates targeting maternal-fetal blood disorders, complement dysregulation, hematology, and metabolic conditions. The company leverages scientific expertise, innovative drug design, and strategic collaborations to create transformative, patient-friendly treatments with high unmet medical needs, aiming to improve outcomes for underserved patient populations worldwide.
This description was generated via AI from an annual report. Updated about 1 year ago.